Ocular Therapeutix, Inc. (OCUL)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Ocular Therapeutix, Inc. (OCUL)
Go deeper and ask any question about OCUL
Company Performance
Current Price
as of Sep 13, 2024$9.00
P/E Ratio
N/A
Market Cap
$1.4B
Description
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Metrics
Overview
- HQBedford, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerOCUL
- Price$9+3.33%
Trading Information
- Market Cap$1.40B
- Float86.91%
- Average Daily Volume (1m)749,514
- Average Daily Volume (3m)1,525,504
- EPS-$1.11
Company
- Revenue$61.10M
- Rev Growth (1yr)8.26%
- Net Income-$43.78M
- Gross Margin90.82%
- EBITDA Margin-259.32%
- EBITDA-$42.63M
- EV$749.44M
- EV/Revenue12.27
- P/EN/A
- P/S24.43
Documents
SEC Filings
Earnings Calls
Factset Street Account